# Phase 1 cholangiocarcinoma trials recruiting: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1 for cholangiocarcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 cholangiocarcinoma trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/cholangiocarcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 31, 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | Iksuda Therapeutics Ltd. | Phase 1 | Not yet recruiting | Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma, PDAC - Pancreatic... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738939) |
| July 21, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump... | National Cancer Institute (NCI) | Phase 1 | Not yet recruiting | Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715903) |
| June 2, 2026 | NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or... | Jonsson Comprehensive Cancer Center | Phase 1 | Recruiting | Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619313) |
| May 29, 2026 | NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | Shanghai Zhongshan Hospital | Phase 1 | Recruiting | Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614061) |
| May 19, 2026 | NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent... | Shenzhen Xinhe Biomedical | Phase 1 | Recruiting | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594964) |
| May 18, 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | University of Pennsylvania | Phase 1 | Recruiting | Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594067) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| January 13, 2026 | NCT07337525 | A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | Pilatus Biosciences Inc | Phase 1 | Recruiting | Advanced Malignant Solid Tumor, Solid Tumor Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07337525) |
| January 12, 2026 | NCT07334119 | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | Myeloid Therapeutics | Phase 1 | Recruiting | HER2-Expressing Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334119) |
| October 9, 2025 | NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Eli Lilly and Company | Phase 1 | Recruiting | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms... | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213791) |
| August 6, 2025 | NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | West China Hospital | Phase 1 | Recruiting | HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer), Pancreatic Ductal... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106827) |
| February 21, 2025 | NCT06840886 | A Study of PHST001 in Advanced Solid Tumors | Pheast Therapeutics | Phase 1 | Recruiting | Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube... | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06840886) |
| December 9, 2024 | NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723236) |
| August 9, 2024 | NCT06546969 | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | University of Maryland, Baltimore | Phase 1 | Recruiting | Biliary Tract Cancer, Cholangiocarcinoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06546969) |
| July 8, 2024 | NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | Chang Gung Memorial Hospital | Phase 1 | Not yet recruiting | Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06490198) |
| March 12, 2024 | NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Massachusetts General Hospital | Phase 1 | Recruiting | Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06302621) |
| February 21, 2024 | NCT06270706 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Pliant Therapeutics, Inc. | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumor | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06270706) |
| November 13, 2023 | NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126406) |
| September 28, 2023 | NCT06058663 | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | Mayo Clinic | Phase 1 | Recruiting | Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06058663) |
| March 17, 2022 | NCT05285358 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract... | City of Hope Medical Center | Phase 1 | Recruiting | Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05285358) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai Zhongshan Hospital | 1 |
| Mayo Clinic | 1 |
| Pilatus Biosciences Inc | 1 |
| Kestrel Therapeutics, Inc. | 1 |
| West China Hospital | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| University of Maryland, Baltimore | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Myeloid Therapeutics | 1 |
| University of Pennsylvania | 1 |
| Pheast Therapeutics | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| Chang Gung Memorial Hospital | 1 |
| Iksuda Therapeutics Ltd. | 1 |
| Pliant Therapeutics, Inc. | 1 |
| City of Hope Medical Center | 1 |
| Massachusetts General Hospital | 1 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 1 |
| Shenzhen Xinhe Biomedical | 1 |
| National Cancer Institute (NCI) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 5 |
| Germany | 1 |
| Japan | 1 |
| Netherlands | 1 |
| Australia | 1 |
| Taiwan | 1 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Steel fabricators in the United States](https://specstream.ai/data/businesses/steel-fabricators/united-states)
- [Cajun and Creole restaurants in the United States](https://specstream.ai/data/businesses/cajun-and-creole-restaurants/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [Generator installation repair companies in the United States](https://specstream.ai/data/businesses/generator-installation-repair-companies/united-states)
